Marco Hernández-Enríquez1,2, Loic Belle3, Hende Madiot3, Michel Pansieri4, Geraud Souteyrand5, Fabiel de Poli6, Christophe Piot7, Ziad Boueri8, Edouard Gerbaud9, Emmanuel Boiffard10, Hakim Benamer11, Benoit Lattuca12, Philippe Commeau13, Richard Gervasoni14, Gregoire Rangé15, Nicolas Lhoest16, Stéphanie Marliere17, Mohamed Abdellaoui18, Nicolas Delarche19, Gilles Zemour20, Jean Armengaud21, Max Carre22, Sebastien Levesque23, Nicolas Boudou2. 1. Cardiology Department, Hospital Universitari General de Catalunya, Barcelona, Spain. 2. Cardiology Department, Rangueil University Hospital, Toulouse, France. 3. Cardiology Department, Hospital of Annecy, Annecy, France. 4. Cardiology Department, Hospital of Avignon, Avignon, France. 5. Cardiology Department, University Hospital of Clermont Ferrand, Clermont-Ferrand, France. 6. Cardiology Department, Hospital of Haguenau, Haguenau, France. 7. Cardiology Department, Private Hospital of Millenaire, Montpellier, France. 8. Cardiology Department, Hospital of Bastia, Bastia, France. 9. Cardiology Department, University Hospital of Bordeaux, Burdeaux, France. 10. Cardiology Department, Hospital of La Roche sur Yon, La Roche sur Yon, France. 11. Cardiology Department, ICPS Massy groupe Ramsay générale de santé, Aubervilliers, France. 12. Cardiology Department, University Hospital of Nîmes, Nîmes, France. 13. Cardiology Department, Private Hospital of Clinique des Fleurs, Ollioule, France. 14. Cardiology Department, University Hospital of Montpellier, Montpellier, France. 15. Cardiology Department, Hospital of Chartres, Chartres, France. 16. Cardiology Department, Private Hospital of L'Orangerie, Strasbourg, France. 17. Cardiology Department, University Hospital of Grenoble, Grenoble, France. 18. Cardiology Department, "Groupement Hospitalier Mutualiste" of Grenoble, Grenoble, France. 19. Cardiology Department, Hospital of Pau, Pau, France. 20. Cardiology Department, Hospital of Cannes, Cannes, France. 21. Cardiology Department, Hospital of Agen, Agen, France. 22. Cardiology Department, Hospital of Auxerre, Auxerre, France. 23. Cardiology Department, University Hospital of Poitiers, Poitiers, France.
Abstract
OBJECTIVES: To evaluate the rate of procedural success and long-term outcomes of the PK Papyrus (PKP) covered stent (CS). BACKGROUND: CS are essential in the treatment of coronary artery perforation (CAP). They have also been used to treat coronary artery aneurysms. Limited evidence is available on clinical outcomes with the PKP. METHODS: This was a multicenter, observational, retrospective, and prospective study. Consecutive patients undergoing intentional PKP implantation in 22 centers in France were included. The primary endpoint was the rate of procedural success. Secondary endpoints included rates of death, myocardial infarction (MI), target lesion revascularization (TLR), in-stent restenosis (ISR), and stent thrombosis (ST). RESULTS: Data from 130 patients were analyzed (mean age 72.5 ± 10.5 years; 71% men). The main indication for PKP was CAP, in 84 patients (65%). Delivery success was achieved in 95% and procedural success in 91%. During the in-hospital stay, 15 patients died (12%) and 7 (5%) presented with ST. Data from 127 patients were available at 19.2 ± 12.8 month follow-up. Thirty-three patients died (26%), 15 (12%) had an MI and 21 (17%) presented with TLR. TLR was due to ISR in 12 patients (9%), 10 had definite ST (8%) and 1 patient for stent under-expansion. CONCLUSIONS: The principal indication for PKP was CAP. PKP had high rates of delivery and procedural success. At long-term follow-up, there was a high rate of TLR, mainly due to ISR and ST. These results are consistent with previously reported data in these clinical settings.
OBJECTIVES: To evaluate the rate of procedural success and long-term outcomes of the PK Papyrus (PKP) covered stent (CS). BACKGROUND: CS are essential in the treatment of coronary artery perforation (CAP). They have also been used to treat coronary artery aneurysms. Limited evidence is available on clinical outcomes with the PKP. METHODS: This was a multicenter, observational, retrospective, and prospective study. Consecutive patients undergoing intentional PKP implantation in 22 centers in France were included. The primary endpoint was the rate of procedural success. Secondary endpoints included rates of death, myocardial infarction (MI), target lesion revascularization (TLR), in-stent restenosis (ISR), and stent thrombosis (ST). RESULTS: Data from 130 patients were analyzed (mean age 72.5 ± 10.5 years; 71% men). The main indication for PKP was CAP, in 84 patients (65%). Delivery success was achieved in 95% and procedural success in 91%. During the in-hospital stay, 15 patients died (12%) and 7 (5%) presented with ST. Data from 127 patients were available at 19.2 ± 12.8 month follow-up. Thirty-three patients died (26%), 15 (12%) had an MI and 21 (17%) presented with TLR. TLR was due to ISR in 12 patients (9%), 10 had definite ST (8%) and 1 patient for stent under-expansion. CONCLUSIONS: The principal indication for PKP was CAP. PKP had high rates of delivery and procedural success. At long-term follow-up, there was a high rate of TLR, mainly due to ISR and ST. These results are consistent with previously reported data in these clinical settings.
Authors: Luca Esposito; Marco Di Maio; Angelo Silverio; Francesco Paolo Cancro; Michele Bellino; Tiziana Attisano; Fabio Felice Tarantino; Giovanni Esposito; Carmine Vecchione; Gennaro Galasso; Cesare Baldi Journal: Front Cardiovasc Med Date: 2022-02-04